Resolutions from Lipidor’s Extraordinary General Meeting
Today, 11 August 2020, Lipidor AB (publ) (the “Company” or “Lipidor”) held an extraordinary general meeting (“EGM”) in Solna, Sweden. The EGM resolved upon, inter alia, the following resolutions.
Resolution on approval of the Company’s subsidiary Emollivet AB’s (the “Subsidiary” or “Emollivet”) resolution on a new issue of shares
The EGM resolved unanimously to approve the Subsidiary’s resolution of 30 June 2020 on a new issue of at most 800 shares in the Subsidiary with deviation from the shareholders’ pre-emption rights (the “New Issue”). The subscription price amounts to SEK 5,000 per share and Emollivet is provided with SEK 4,000,000 on full subscription. Provided that the New Issue is fully subscribed for, the corresponding dilution effect amounts to approximately 42.1 percent of the total number of shares and votes in Emollivet. Lipidor will own 951 shares in Emollivet after the New Issue corresponding to approximately 50.1 percent of the total number of shares and votes in Emollivet. The resolution was made in accordance with the proposal which was included in the notice convening the EGM and which can be read on the Company’s website www.lipidor.se.
Resolution on approval of Emollivet’s resolution on a long-term incentive program
